Compile Data Set for Download or QSAR
maximum 50k data
Found 29 of ic50 for UniProtKB: P00533
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494877(US10994015, Example 11)
Affinity DataIC50:  0.140nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494873(US10994015, Example 7)
Affinity DataIC50:  1nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495019(US10994015, Example 319)
Affinity DataIC50:  1.30nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494874(4-((17-(4-(4-(4-((2-chlorobenzyl)amino)-7H-pyrrolo...)
Affinity DataIC50:  1.70nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494875(US10994015, Example 9)
Affinity DataIC50:  1.90nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494867((2S,4R)-1-((S)-2-(tert-butyl)-14-(4-(4-(4-((2-chlo...)
Affinity DataIC50:  2.10nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494872(US10994015, Example 6)
Affinity DataIC50:  2.90nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494868(US10994015, Example 2)
Affinity DataIC50:  4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494871(US10994015, Example 5)
Affinity DataIC50:  4.10nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494870(US10994015, Example 4)
Affinity DataIC50:  4.20nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494869(US10994015, Example 3)
Affinity DataIC50:  5.5nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495017(US10994015, Example 313 | US10994015, Example 314)
Affinity DataIC50:  7.5nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494922(US10994015, Example 13)
Affinity DataIC50:  37nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495012(US10994015, Example 308)
Affinity DataIC50:  53nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494879(US10994015, Example 12)
Affinity DataIC50:  83nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494924(US10994015, Example 15)
Affinity DataIC50:  140nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495016(US10994015, Example 312)
Affinity DataIC50:  170nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494923((2S,4R)-1-((S)-2-(tert-butyl)-14-(4-(4-((2-chlorob...)
Affinity DataIC50:  200nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495010(US10994015, Example 306)
Affinity DataIC50:  380nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495005(2-(2,6-dioxopiperidin-3-yl)-5-(4-(3-(4-(4-(2-((1-i...)
Affinity DataIC50:  1.60E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495013(US10994015, Example 309)
Affinity DataIC50:  1.90E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494876(US10994015, Example 10)
Affinity DataIC50:  3.70E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495011(2-(7-((4-(3-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3...)
Affinity DataIC50:  3.80E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495014(US10994015, Example 310)
Affinity DataIC50:  6.00E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494931(US10994015, Example 73)
Affinity DataIC50:  8.10E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495015(US10994015, Example 311)
Affinity DataIC50:  9.00E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM495017(US10994015, Example 313 | US10994015, Example 314)
Affinity DataIC50:  1.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494928(2-(2,6-dioxopiperidin-3-yl)-5-(2-(2-(2-((1-isoprop...)
Affinity DataIC50: >3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-745,747-749,751-1210](Homo sapiens (Human))
Arvinas Operations

US Patent
LigandPNGBDBM494929(2-(2,6-dioxopiperidin-3-yl)-5-(4-(2-((1-isopropyl-...)
Affinity DataIC50: >3.00E+4nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent